OLIVERI Maria Beatriz
congresos y reuniones científicas
Bone Mineral Density Improvement After Two Years of Intravenous Pamidronate Treatment of Patients with Fibrous Dysplasia
PARISI MS; OLIVERI B; MAUTALEN CA.
Congreso; XXIV Congreso Anual de la ASBMR; 2002
American Society for Bone and Mineral Research
Intravenous Pamidronate (APD) has proved to be effective in patients with FibrousDysplasia (FD) as shown by its effect on bone pain, markers of bone turnover orradiological changes.We report the effect of two years treatment with intravenous APD (180mg, 60mg/dayduring 3 days, every 6 months) on BMD of affected bones in 10 patients with FD, 7 womenand 3 men (mean age 32 years). Clinical symptoms and markers of bone turnover wereevaluated every 3 months. BMD of total skeleton and X-rays of FD areas were performedat baseline and once a year. BMD of FD areas was compared with the contralateral side(CL) using the region of interest program on the total skeleton scan.At baseline the average difference in BMD of FD areas was 11.2% compared with CL (asignificantly greater difference than that observed between left and right sides in healthycontrols 0.7% (p<0.02)).Treatment with intravenous APD improved clinical symptoms and significantly decreasedvalues of bone markers. Mean total skeleton BMD increased 2.7% (p<0.05) after 12months and 4.4% (p<0.05) after 24months. BDM of FD areas Increased 3.8% after 12months and 8.2% after 24 months compared with 0.3% and 2.9% changes in CLrespectively. Average difference BMD of FD areas diminished to 8.4% after 12 monthsand 2.6% (p<0.02) after 24 months compared with CL. No radiographics changes wereobserved in FD lesions.Intravenous APD increased BMD of both the total skeleton and Fibrous Dysplasia affectedbones BMD. Densitometric follow-up of these patients is a useful tool to evaluate theefficacy of treatment and is more sensitive to detect early changes than radiology.